Diagnosis and treatment of thrombotic microangiopathy.
Int J Lab Hematol
; 44 Suppl 1: 101-113, 2022 Sep.
Article
in English
| MEDLINE | ID: covidwho-2063738
ABSTRACT
Thrombotic microangiopathy (TMA) is characterized by thrombocytopenia, microangiopathic haemolytic anaemia and end organ damage. TMAs have varying underlying pathophysiology and can therefore present with an array of clinical presentations. Renal involvement is common as the kidney is particularly susceptible to the endothelial damage and microvascular occlusion. TMAs require rapid assessment, diagnosis, and commencement of appropriate treatment due to the high morbidity and mortality associated with them. Ground-breaking research into the pathogenesis of TMAs over the past 20 years has driven the successful development of targeted therapeutics revolutionizing patient outcomes. This review outlines the clinical presentations, pathogenesis, diagnostic tests and treatments for TMAs.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Thrombotic Microangiopathies
Type of study:
Diagnostic study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Int J Lab Hematol
Journal subject:
Hematology
Year:
2022
Document Type:
Article
Affiliation country:
Ijlh.13954
Similar
MEDLINE
...
LILACS
LIS